Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AFAffimed N.V. logo

Affimed N.V. (AFMD)

NASDAQ Global Market · Currency in USD
$0.18 ▲ +0.00 (+0.00%)
At close: Mar 12, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.18
Open
$0.18
Day's Range
$0.18 – $0.18
52 Week Range
$0.02 – $8.95
Volume
22,062,730
Avg. Volume
15,650,229
Market Cap
$2.98M
Beta (5Y Monthly)
2.07
PE Ratio (TTM)
--
EPS (TTM)
-$7.09
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$7.50

Profile: Affimed N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
76
CEO
Shawn Leland

Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma.

Earnings

DateEst.Actual
Jun 11, 2025-$0.52-$0.62Miss
Mar 27, 2025-$0.91-$0.87Beat
Nov 14, 2024-$1.14-$1.03Beat
Sep 5, 2024-$1.00-$1.09Miss
Jun 12, 2024-$1.73-$1.38Beat
Mar 28, 2024-$1.59-$1.35Beat

Analyst view

Consensus price target
$7.50 ▲ +4,032.2%
Range $5.00 – $10.00
Rating: Buy
Buy 55% · Hold 45% · Sell 0%

Get free alerts on AFMD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.